Search Results
-
Post
United Healthcare Issues Positive Coverage Decision for Optune
...130 million Americans had coverage of Optune. United Healthcare’s positive coverage policy of Optune adds to positive coverage policies from Harvard Pilgrim Healthcare, Oregon Health Plan and Blue Cross Blue...
-
Post
NCCN Guidelines Recommend Optune in Combination with Temozolomide as a Category 1 Treatment for Newly Diagnosed Glioblastoma
...www.twitter.com/novocure. Approved Indications Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the...
-
Post
Blue Cross Blue Shield of Michigan Issues Positive Coverage Decision for Optune
More than 112 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma May 04, 2016 07:30 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS...
-
Post
FDA Approves Investigational Device Exemption for RTOG Trial of Novocure’s Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
...NVCR) announced today that the RTOG Foundation will conduct a phase 2 pilot trial testing Optune together with bevacizumab for patients with bevacizumab-refractory recurrent glioblastoma (GBM). The RTOG Foundation recently...
-
Post
Humana Issues Positive Coverage Decision For Optune
More than 107 million Americans now have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma March 03, 2016 07:30 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS...
-
Post
Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States
...and has very limited treatment options. Tumor Treating Fields (TTFields) therapy delivered by Optune is FDA-approved for recurrent GBM. Optune is a novel anti-mitotic therapy that is available in the...
-
Post
New Phase 3 Data show Optune in Combination with Second Line Chemotherapy is Superior to Second Line Chemotherapy Alone in Glioblastoma Patients at First Recurrence
...use Optune under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.optune.com/safety or by calling toll free 1-855-281-9301 in the...
-
Post
Retrospective Analysis Shows Optune Safe in Glioblastoma Patients with Implanted Non-Programmable Shunts
...a pre-existing contraindication in October 2015 stating that Optune should not be used in patients with non-programmable shunts. “The removal of the contraindication from its regulatory labeling increases Optune’s addressable...
-
Post
FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma
...HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its Premarket Approval (PMA) application for Optune has been accepted for filing and review and granted priority review status...
-
Post
Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update
...approval (PMA) supplement application for the second generation Optune System. The second generation Optune system is less than half the weight and size of the first generation Optune System and...